|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- Latvian Banker Taking Souls as Collateral
- US Home Prices Seen Falling 40% Overall: Analyst
- The Rising Mountain of Debt May Be the Next Crisis
- The Worst Expected 2010 State Budget Gaps
- NY City Apartment Sales Down More Than 50%
- SEC May Reinstate Rules for Short-Selling Stocks
- Malaysia PM Speaks to CNBC
- Health Care on Brink of IT Revolution
- Alaska Governor Sarah Palin Will Resign
- The Rising Mountain of Debt May Be the Next Crisis
- North Korea Fires Short Range Missiles: Reports
- SEC May Reinstate Rules for Short-Selling Stocks
- Major Nations Should Back the Dollar: Japan
- Earnings Season: A Likely Game-Changer
- Slideshow: Best-Selling Fourth of July Fireworks
- Latvian Banker Taking Souls as Collateral
- OPEC President Says Is Satisfied with Current Oil Price
- Divisions Dominate as Third Quarter Begins
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
Text Size 
Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.
Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA
Loading...
()
], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.
"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."
A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.
"In the end it could make sense, but of course that all depends on the price," Kulhoff said.
RELATED LINKS
It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.
Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.
"That could be the start of a bigger M&A wave," she added.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes